IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
56.98
+0.33 (+0.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close56.65
Open56.29
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range55.87 - 57.08
52 Week Range48.27 - 86.58
Volume641,561
Avg. Volume1,016,303
Market Cap8.015B
Beta (3Y Monthly)1.89
PE Ratio (TTM)18.84
EPS (TTM)3.03
Earnings DateNov 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est68.27
  • Thomson Reuters StreetEvents

    Edited Transcript of IONS earnings conference call or presentation 6-Nov-19 4:30pm GMT

    Q3 2019 Ionis Pharmaceuticals Inc Earnings Call

  • Ionis Pharmaceuticals to present at upcoming investor conferences
    PR Newswire

    Ionis Pharmaceuticals to present at upcoming investor conferences

    Details on presentation times or changes to presentation dates can be found on the Company's website. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.

  • Here's One Drugmaker That Popped On Earnings — And Two That Didn't
    Investor's Business Daily

    Here's One Drugmaker That Popped On Earnings — And Two That Didn't

    Shares of Ionis Pharma jumped Wednesday after the biotech's third-quarter sales and profit easily topped Wall Street's estimates. But Perrigo and Elanco stocks dipped after their reports.

  • Ionis Pharmaceuticals (IONS) Q3 Earnings and Revenues Beat Estimates
    Zacks

    Ionis Pharmaceuticals (IONS) Q3 Earnings and Revenues Beat Estimates

    Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 158.06% and 11.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Ionis provides third quarter financial results and improved 2019 guidance
    PR Newswire

    Ionis provides third quarter financial results and improved 2019 guidance

    Year-to-date revenues increased more than 50% to nearly $630 million Ionis increases 2019 revenue guidance to $1 billion Ionis significantly improves operating income and net income guidance Webcast today, ...

  • Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
    Zacks

    Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
    PR Newswire

    Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference

    - Ionis' C. Frank Bennett, Ph.D., head of research, to give keynote address - 15 presentations highlighting the transformational potential of LICA medicines for a broad range of rare and common diseases ...

  • Ionis Pharmaceuticals Enters Oversold Territory
    Zacks

    Ionis Pharmaceuticals Enters Oversold Territory

    Ionis Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences
    PR Newswire

    Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences

    CARLSBAD, Calif., Oct. 23, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that Ionis' Chairman and Chief Executive Officer, Stanley T. Crooke, M.D., Ph.D., is one of two scientists to be awarded the 2019 Massry Prize. Dr. Crooke, who founded Ionis 30 years ago to create a radically different drug discovery platform, was recognized by the Massry Foundation for his pioneering work to establish an entirely new chemical class of medicines, antisense oligonucleotides.

  • Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
    PR Newswire

    Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast

    CARLSBAD, Calif., Oct. 22, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.

  • GlobeNewswire

    Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, November 5th at 4:30 p.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.

  • Is Ionis Pharmaceuticals, Inc. (IONS) A Good Stock To Buy?
    Insider Monkey

    Is Ionis Pharmaceuticals, Inc. (IONS) A Good Stock To Buy?

    There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]

  • TheStreet.com

    Ionis Jumps After Vote of Confidence in Drug Pipeline

    A Wells Fargo analyst sees big potential in Ionis' new pipeline of drugs based on antisense oligonucleotide technology, which could prove key in the battle against ALS.

  • Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
    PR Newswire

    Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting

    - Ionis scientists, including CEO Stanley Crooke, M.D., Ph.D., recognized with prestigious Paper of the Year Award for their work on advancing core antisense research - Ionis' Holly Kordasiewicz, Ph.D., ...

  • Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates
    Zacks

    Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

    Key highlights of the past week include label expansion of drugs, licensing deals and more.

  • Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
    PR Newswire

    Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results

    Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that the company has been notified by its partner Bayer about the decision to advance IONIS-FXI-LRx following positive clinical results. IONIS-FXI-LRx is an antisense medicine being developed to treat patients with clotting disorders. IONIS-FXI-LRx utilizes Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI (FXI), a clotting factor produced in the liver.

  • How A Deal With Pfizer Sent This Pharma Stock Rocketing In High Volume
    Investor's Business Daily

    How A Deal With Pfizer Sent This Pharma Stock Rocketing In High Volume

    Shares of Akcea Therapeutics rocketed in higher-than-average volume on Monday after the Ionis Pharmaceuticals affiliate announced a licensing deal with Dow Jones component Pfizer.

  • Does Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Pay Compare Well With Peers?
    Simply Wall St.

    Does Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Pay Compare Well With Peers?

    Stan Crooke became the CEO of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in 1989. This analysis aims first to contrast...

  • GlobeNewswire

    Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (IONS) and Pfizer Inc. (PFE), today announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases. AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3 (ANGPTL3) protein in the liver, a key regulator of triglycerides, cholesterol, glucose and energy metabolism. “AKCEA-ANGPTL3-LRx has the potential to treat people suffering from certain cardiovascular and metabolic diseases.

  • With eyes on IPO, muscular dystrophy startup names new CEO
    American City Business Journals

    With eyes on IPO, muscular dystrophy startup names new CEO

    The scientific founder and CEO of Cambridge startup Dyne Therapeutics has hired a new CEO — a former CFO with experience in public stock offerings. Dyne’s current CEO, Romesh Subramanian, will be replaced by Joshua Brumm, who is leaving his post as CFO of Lexington microbiome startup Kaleido Biosciences and who has taken a California startup public.

  • Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN
    Zacks

    Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN

    Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

  • Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year
    PR Newswire

    Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year

    CARLSBAD, Calif., Sept. 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that the California Life Sciences Association (CLSA), the trade association representing California's life sciences sector and its board of directors will honor Ionis with the 2019 Pantheon DiNA™ Award for Company of the Year. The award recognizes Ionis' ongoing commitment to growing the life sciences sector in Southern California and for achieving the approval and commercialization of SPINRAZA®, TEGSEDI® and WAYLIVRA® in major markets around the world. The award will be presented at CLSA's 16th Annual Pantheon DiNA™ Awards ceremony Nov. 15, in San Francisco, Calif.

  • MarketWatch

    Akcea's stock drops after 3 top executives leave company, including CEO

    Shares of Akcea Therapeutics Inc. sank 10% in morning trade Monday, after the biopharmaceutical company three of its top executives were leaving the company, including Chief Executive Paula Soteropoulos, effective immediately. The others leaving were President Sarah Boyce and Chief Operating Officer Jeff Goldberg. The company, which is a majority-owned affiliate of Ionis Pharmaceuticals Inc. , said it named Damien McDevitt as interim-CEO. McDevitt was previously chief business officer at Ionis. Akcea said Michael Yang and Joseph Klein have jointed its board of directors. Ionis shares tacked on 0.3%. Over the past 12 months, shares of Akcea have tumbled 27.8%, Ionis have rallied 28.0% and the S&P 500 has gained 2.0%.

  • Biogen's New Study to Test Higher Dose of SMA Drug Spinraza
    Zacks

    Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

    Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.